
Sign up to save your podcasts
Or


When the FDA approved an RSV vaccine for infants in July of 2023, parents and pediatricians rejoiced. But product shortages and a patchwork of insurance coverage throttled the rollout, leaving many babies still unprotected this winter. Pediatrician and Internist Dr. Wendie Grader-Beck talks with Dr. Josh Sharfstein about her frustrations around implementation, and what needs to be done before the next RSV season for this lifesaving technology to fulfill its promise.
By The Johns Hopkins Bloomberg School of Public Health4.6
618618 ratings
When the FDA approved an RSV vaccine for infants in July of 2023, parents and pediatricians rejoiced. But product shortages and a patchwork of insurance coverage throttled the rollout, leaving many babies still unprotected this winter. Pediatrician and Internist Dr. Wendie Grader-Beck talks with Dr. Josh Sharfstein about her frustrations around implementation, and what needs to be done before the next RSV season for this lifesaving technology to fulfill its promise.

43,628 Listeners

40 Listeners

5 Listeners

26 Listeners

5 Listeners

259 Listeners

56,550 Listeners

493 Listeners

9 Listeners

45 Listeners

94 Listeners

16,373 Listeners

16 Listeners

4,761 Listeners

2 Listeners

4,482 Listeners

389 Listeners

6,552 Listeners

25 Listeners

6,398 Listeners

231 Listeners

66 Listeners

166 Listeners

110 Listeners